| Biological Information | |
|---|---|
| Background Information: | SETD7 (SET domain-containing protein 7) is a lysine methyltransferase that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to the lysine 4 residue of histone H3 (H3K4), leading to the formation of monomethylated H3K4. SETD7 is a member of the SET domain-containing protein family and is the only known enzyme that specifically methylates H3K4 in a monomethylated form.
SETD7 is dysregulated in various types of cancer, including breast cancer, prostate cancer, and hepatocellular carcinoma. Its dysregulation has been linked to aberrant gene expression, genome instability, and defects in DNA repair, which can contribute to the development and progression of cancer.
SETD7 is an important epigenetic protein with potential therapeutic applications. Its inhibition has been shown to suppress tumor growth and improve insulin sensitivity in preclinical models of cancer and diabetes, respectively. |
| Target Class: | Epigenetic Protein |
| Accession Number: | Refer to CoA for Accession Number |
| Target Name: | SETD7 |
| Target Species: | Human |
| Usage | |
| Product Type: | Enzymes |
| Application: | Drug Discovery & Development |
| Storage Conditions: | 1 year at -70°C |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
SETD7
C-terminal 6His-tagged recombinant, human SETD7 amino acids 1-366.
Datasheets
EPI056 Datasheet
View Document